EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Revisiting the Gray Zone in HBeAg-Negative Chronic Hepatitis B: Insights From a Multicenter Liver Biopsy Cohort

Özlem Gül iD, Hüseyin Köseoğlu iD, Selim Yalçın iD, Barış Yılmaz, Dilek Oğuz iD, Sema Zergeroğlu iD, Bilal Ergül iD

Turkish Journal of Gastroenterology · 11.08.2026

DOI: 10.5152/tjg.2026.26367 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Turkish Journal of Gastroenterology, online erschienen am 11.08.2026. Verfasst von Özlem Gül und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Lokman Hekim University Faculty of Medicine, Ankara, Türkiye. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B e Antigens, Liver, Liver Cirrhosis. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: The management of patients with HBeAg-negative chronic hepatitis B (CHB) with intermediate viremia and persistently normal alanine aminotransferase (ALT) levels remains controversial. This “gray-zone” (GZ) population may harbor significant histological liver injury despite not meeting conventional treatment criteria. This study characterized the histologic features of this GZ population and compared their clinical and laboratory characteristics. Materials and Methods: In this multicenter retrospective study, patients with HBeAg negative CHB who had hepatitis B virus (HBV) DNA levels between 2000 and 20 000 IU/mL and persistently normal ALT levels and who underwent liver biopsy between 2014 and 2022 were included. Histological assessment was performed using the modified Ishak scoring system. Significant fibrosis was defined as Ishak stage of 2 or greater. Clinical, virological, and noninvasive fibrosis parameters were analyzed.

Results

A total of 145 patients were included (mean age: 46.3 ± 12.6 years; 54.5% female). Significant fibrosis and/or moderate-tosevere necroinflammatory activity requiring antiviral therapy was identified in 109 patients (75.1%). Although ALT and aspartate aminotransferase levels remained within normal reference range, both were significantly higher in the treatment group compared than in the nontreatment group (P = .003 and P = .018, respectively). Aspartate aminotransferase-to-platelet ration index (APRI) scores were also significantly elevated among treated patients (P = .02), whereas Fibrorsis-4 (FIB-4) scores did not differ significantly. HBV DNA and quantitative Hepatitis B surface antigen (HBsAg) levels were comparable between groups.

Conclusion

A substantial proportion of patients with HBeAg-negative CHB in the GZ exhibited clinically significant histologic disease despite persistently normal ALT levels. Reliance solely on conventional biochemical thresholds may underestimate the burden of fibrosis. Early histological evaluation and more proactive treatment strategies should be considered for selected patients in the GZ. Cite this article as: Gül Ö, Köseoğlu H, Yalçın S, et al. Revisiting the gray zone in HBeAg negative chronic hepatitis B: Insights from a multicenter liver biopsy cohort. Turk J Gastroenterol. Published online August 11, 2026. doi: 10.5152/tjg.2026.26367.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B e AntigensLiverLiver CirrhosisHumansFemaleMaleMiddle AgedRetrospective StudiesAdultBiopsyAlanine TransaminaseAspartate AminotransferasesDNA, ViralHepatitis B virusAntiviral Agents

Stichwörter der Autor:innen

Chronic hepatitis BHBeAg-negative chronic hepatitis Bgray zoneliver biopsynormal ALTsignificant fibrosis

Substanzen

Hepatitis B e AntigensAlanine TransaminaseAspartate AminotransferasesDNA, ViralAntiviral Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Lokman Hekim University Faculty of Medicine, Ankara, Türkiye.
  • Department of Gastroenterology, Hitit University Faculty of Medicine, Çorum, Türkiye.
  • Department of Oncology, Kırıkkale University Faculty of Medicine, Kırıkkale, Türkiye.
  • Department of Pathology, Kırıkkale University Faculty of Medicine, Kırıkkale, Türkiye.

ORCID-Profile: Özlem Gül, Hüseyin Köseoğlu, Selim Yalçın, Dilek Oğuz, Sema Zergeroğlu, Bilal Ergül

Zitieren

APA

Gül, Ö., Köseoğlu, H., Yalçın, S., Yılmaz, B., Oğuz, D., Zergeroğlu, S., & Ergül, B. (2026). Revisiting the Gray Zone in HBeAg-Negative Chronic Hepatitis B: Insights From a Multicenter Liver Biopsy Cohort. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2026.26367

Vancouver

Gül Ö, Köseoğlu H, Yalçın S, Yılmaz B, Oğuz D, Zergeroğlu S, et al. Revisiting the Gray Zone in HBeAg-Negative Chronic Hepatitis B: Insights From a Multicenter Liver Biopsy Cohort. Turkish Journal of Gastroenterology. 2026. doi:10.5152/tjg.2026.26367

BibTeX
@article{Gl2026,
  author = {Gül, Özlem and Köseoğlu, Hüseyin and Yalçın, Selim and Yılmaz, Barış and Oğuz, Dilek and Zergeroğlu, Sema and Ergül, Bilal},
  title = {Revisiting the Gray Zone in HBeAg-Negative Chronic Hepatitis B: Insights From a Multicenter Liver Biopsy Cohort},
  journal = {Turkish Journal of Gastroenterology},
  year = {2026},
  doi = {10.5152/tjg.2026.26367}
}
Kostenlos starten →